Clinical trial
Transcriptomics and Epigenetics Analysis for Biomarkers Identification Involved in Drug-resistance Mechanisms of Multiple Myeloma
NCT05888636 is registered in ClinicalTrials.gov with Regina Elena Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Transcriptomics and Epigenetics Analysis for Biomarkers Identification Involved in Drug-resistance Mechanisms of Multiple Myeloma
- Lead sponsor
- Regina Elena Cancer Institute
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- June 18, 2019
- Completion date
- December 31, 2024
- Enrollment
- 200 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.